Study on the effect of Lenalidomide combined with Bortezomib and Dex-amethasone in the treatment of multiple myeloma and its effect on im-mune function
Objective To study the effect of Lenalidomide combined with Bortezomib and Dexamethasone in the treatment of multiple myeloma and its effect on immune function.Methods A total of 80 patients with multiple myeloma admitted to Huangshan City People's Hospital from June 2018 to June 2022 were selected for study,they were divided into control group and observation group according to random number table method,with 40 cases in each group.The control group was treated with Bortezomib and Dexamethasone,while observation group was treated with Lenalidomide on the basis of control group,at least treatment for two courses.The clinical efficacy of two groups was compared;the levels of CD3+,CD4+,and CD4+/CD8+before and after treatment were compared between two groups;the incidence of cytogenetic risk before and after treatment was compared between two groups.Results The clinical efficacy of observation group was better than that of control group(P＜0.05).After treatment,the levels of CD3+,CD4+,and CD4+/CD8+in both groups were higher than those before treatment,and those of observation group were higher than those of control group(P＜0.05).After treatment,the incidence of cytogenetic risk in both groups were lower than those before treatment,and that of observation group was higher than that of control group(P＜0.05).Conclusion Lenalidomide combined with Bortezomib and Dexamethasone has a significant effect in the treatment of multiple myeloma,which can effectively reduce the inflammatory reaction,improve the immune function,and promote rehabilitation,and is worthy of clinical promotion and application.
NETL
NSTL
万方数据
